Richard Miller is a Dermatology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8220 Us Highway 19
Port Richey, FL 346686639
Telephone
727-841-8505Registry record last updated 15 Sept 2010.
Clinical trials
- Beta-Blocker Heart Attack Trial (BHAT)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
40 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202511 payments
- Regeneron Healthcare Solutions, Inc.Program year20254 payments
- Galderma Laboratories, L.P.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
34.1%Corticosteroid24.4%Triamcinolone Acetonide68%Triamcinolone acetonide33%Part D + Part B≥96 patientsAntivirals5.1%Imiquimod100%Part D≥21 patients+ 2 more classes in this area
Anti-infectives
22.5%Tetracycline-class Drug6.6%Doxycycline Hyclate100%Part D≥31 patientsAzole Antifungal5.9%Ketoconazole100%Part D≥19 patients+ 3 more classes in this area
Respiratory
13.9%RNA Synthetase Inhibitor Antibacterial9.5%Mupirocin100%Part D≥51 patientsCorticosteroid4.3%Mometasone Furoate100%Part D≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1997–2000 per NIH RePORTER. The latest:
- G PROTEIN-DEPENDENT SIGNALING IN RENAL EPITHELIAL CELLS
University of Florida
FY2000$122,287R01DK041726
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”